Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
Clinical trial NCT05686434 · RECRUITING
Trial details
- NCT number
- NCT05686434
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-14
- Primary completion
- 2024-10-14
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.